Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gabapentin + lidocaine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Gabapentin + lidocaine is a fixed-dose combination of two drugs used primarily for the treatment of neuropathic pain, including conditions such as diabetic neuropathy, postherpetic neuralgia, and chronic nerve pain. Gabapentin is an anticonvulsant that works by binding to voltage-gated calcium channels (specifically the alpha 2 delta subunit), reducing neuronal excitability and modulating neurotransmitter release to relieve nerve pain. Lidocaine is a local anesthetic that blocks sodium channels on nerve cell membranes, inhibiting the initiation and conduction of nerve impulses to provide temporary numbing and reduce pain sensation. Together, this combination offers both immediate local analgesia from lidocaine and longer-term modulation of neuropathic pain from gabapentin[1][5][7][8].
- Brand names
- SentidorProgabaLidogabGapitas-LAdgabaGabapax LPodosoftElvixGabasmoothGabaquil
- Other names
- Mgaba LC
02
Targets
CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)CACNA2D2 (α2δ-2)
Beyond the preview
Go deeper on gabapentin + lidocaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gabapentin + lidocaine.